Floatz logo

DOXORUBICIN

Inflammatory Breast Carcinoma

M.D. Anderson Cancer CenterSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Inflammatory Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Hoffmann-La Roche
Phase 3BBB
Cyclophosphamide
Northwestern University
Phase 3BBB
Carboplatin
Northwestern University
Phase 3BBB
Docetaxel
Association Tunisienne de lutte Contre le Cancer
Phase 3BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Hoffmann-La Roche
Phase 3BBB

View all 49 →

Same molecule, other indications

DOXORUBICIN is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
77 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →